Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of BI 764198 With and Without Itraconazole in Healthy Males
NCT07308652Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Feb 2026
- Primary completion
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of apecotrep in focal segmental glomerulosclerosis (FSGS), sponsored by Boehringer Ingelheim. Primary endpoints: Area under the concentration-time curve from zero extrapolated to infinity and Maximum measured concentration. Started Feb 2026; status: completed.
02
Drugs
apecotrep
03
Conditions
focal segmental glomerulosclerosis (FSGS)
Beyond the preview
Go deeper on NCT07308652.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07308652.